Breast Cancer Long-term Outcome of Cardiac Dysfunction

NCT ID: NCT01904331

Last Updated: 2018-06-15

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 700 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-06-30
• Study Completion Date: 2017-10-24

Brief Summary

The purpose of this study is to assess the prevalence of cardiac dysfunction and (undiagnosed) heart failure in women registered in general practice with a history of breast cancer who received chemotherapy and / or radiotherapy as compared to a matched female control population.

Detailed Description

Background:

Due to screening and progress in treatment the overall survival of women treated for breast cancer has increased over the last decades. Therefore, the long-term effects of breast cancer have emerged as an important topic. An increased mortality is seen within years post treatment due to an increased incidence of cardiac dysfunction among survivors of breast cancer. This increased mortality is related to long term side effects of treatment with chemotherapy and radiotherapy. Earlier studies into this topic have focused on specific patient groups and therefore these results are difficult to translate to the general population. Furthermore, most echo graphic studies have focused on the systolic dysfunction of the heart, which is a late stage of the cardiac deterioration. Detecting cardiotoxicity early on provides the opportunity for early treatment and might therewith prevent deterioration of cardiac function and improve the prognosis of patients

Objectives:

Primary objective

1. To assess the risk of a systolic and / or diastolic cardiac dysfunction at echocardiography of breast cancer patients compared to matched controls.

Secondary objective:

2. To assess the risk of heart failure( a combination of clinical complaints, objective measures at physical examination, laboratory examination or echocardiography) in breast cancer patients as compared to matched controls

3. To determine the value of patient characteristics, clinical complaints and signs in physical examination in diagnosing cardiac dysfunction as found of echocardiography

4. To determine the additional diagnostic value of biomarkers; N-terminal pro-hormone of brain natriuretic peptide (NT-pro-BNP) and high sensitive troponin T (hs-troponinT) in diagnosing cardiac dysfunction, as found on echocardiography

5. Genetic analysis

Study design and population:

This is a cross-sectional, observational study in women in general practice who have been curatively treated for breast cancer with chemo and / or radiotherapy at a minimum of 5 years ago and an age and general practitioner (GP) matched female control population. Patients must be 18 years or older, younger than 80 at the time of diagnosis, not been treated for other types of cancer with chemo- and/or radiotherapy and must be willing to give written informed consent Primary study parameters

1. Systolic and diastolic cardiac function of echocardiography

2. Hospital Anxiety and Depression Scale (HADS)

3. Multi dimensional Fatigue Inventory (MFI-20)

4. Cardiovascular Risk Management (CVRM)

5. Short physical examination: blood pressure, height, weight, waist circumference, electrocardiography, signs of edema, auscultation

6. Laboratory testing: Hemoglobin, hematocrit, leucocytes, creatinine , estimated glomerular filtration rate (GFR), cholesterol, triglycerides, High-density lipoprotein (HDL) cholesterol, Low-density lipoprotein (LDL) cholesterol, Cholesterol/HDL ratio, C-reactive protein (CRP),Thyroid stimulating hormone (TSH), glucose

7. Serum and plasma for biomarkers

8. ethylenediaminetetraacetic acid (EDTA) -tube for DeoxyriboNucleic Acid (DNA) analysis Outcomes

Primary outcome:

The cardiac dysfunction will be related to type of therapy and compared to the age-and general practice matched control group. Information on type of therapy will be gathered trough contacting the hospitals were patients were treated.

Secondary outcome:

Symptoms and signs of women with cardiac dysfunction will be compared with those without cardiac dysfunction. A comparison between women treated for breast cancer and women without breast cancer will be made.

The level of the biomarkers will be linked with the cardiac dysfunction. In women treated for breast cancer with chemo- and/or radiotherapy these will also be linked with type of therapy.

DNA analysis will be carried out to investigate if changes in candidate genes are related to the development of cardiac dysfunction.

Burden and risks associated with participation, benefit and group relatedness The minimal invasive tests will be performed if patient are willing to participate in de study after contact trough letters. As far as known no serious adverse events are linked to the described study procedures.

With this study we hope to get insight in the risk of cardiac dysfunction after chemo- and/or radiotherapy in women treated for breast cancer. And to determine possibly diagnostic measure to detect this deterioration. Eventually, this may contribute to the early detection of cardiac dysfunction in women treated with chemo- and/or radiotherapy for breast cancer to improve the prognosis for patients.

Conditions

Breast Neoplasms

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: CROSS_SECTIONAL

Study Groups

Breast cancer patients

Women who were curatively treated with chemo- and/or radiotherapy for breast cancer

No interventions assigned to this group

Controls

Women matched on age and general practitioner with the breast cancer patients

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• For breast cancer patients: minimum of 5 years after treatment for breast cancer with chemo- and/or radiotherapy and after 1970
• For breast cancer patients: younger than 80 at the time of diagnosis of breast cancer
• willing to sign an informed consent
• older than 18 at the time of inclusion

Exclusion Criteria

• Treatment with chemo- and/or radiotherapy for other types of cancer besides breast cancer
• women who are unable to participate (e.g. terminally or mentally ill)

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

University Medical Center Groningen

OTHER

Sponsor Role: lead

Responsible Party

Dr. A.J. Berendsen

Dr.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Marjolein Y Berger, M.D. Ph.D.

Role: STUDY_DIRECTOR

University Medical Center Groningen

Locations

University Medical Center Groningen (UMCG)

Groningen, , Netherlands

Countries

Netherlands

Other Identifiers

686317

Identifier Type: -

Identifier Source: org_study_id